D-0355-2023 Class II Terminated
FDA drug recall D-0355-2023 was initiated by Nephron Sterile Compounding Center LLC on Feb 22, 2023 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Sep 24, 2024). Affected quantity: 4,743 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 8, 2023
- Initiation Date
- Feb 22, 2023
- Termination Date
- Sep 24, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4,743 bottles
Product description
Diltiazem HCl in 0.7% Sodium Chloride Injection, 125 mg/125 mL (1 mg/mL), 125 mL Single-Dose Container bottle, packaged in 15 x 1 IV Bottles per carton, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th St. Extension, West Columbia, SC 29172, NDC 69374-997-15.
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
Nationwide in the USA
Code information
Lots: DS2053, Exp. 2/27/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0355-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026